Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 10, 2021
02 February 2021 - 11:30PM
Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that fourth quarter and fiscal year 2020
financial results will be released after the market closes on
Wednesday, March 10th.
Management will host a conference call at 5:00 p.m. Eastern Time
on March 10th to discuss the results of the quarter and fiscal
year. Those who would like to participate may dial 877-407-2988
(201-389-0923 for international callers) and provide access code
13715793. A live webcast of the call will also be provided on the
Events section of the Company's investor relations website and can
be accessed directly via the following link:
https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/43341/indexl.html.
For those unable to participate, a replay of the call will be
available for two weeks at 877-660-6853 (201-612-7415 for
international callers); access code 13715793. The webcast will be
archived on the Events section of the Company’s investor relations
website.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS™). For more information, visit
www.heliusmedical.com.
About the PoNS Device and PoNS
Treatment
The Portable Neuromodulation Stimulator (PoNS) is an authorized
class II, non-implantable medical device authorized for sale in
Canada. PoNS is intended as a short term treatment (14 weeks) of
gait deficit due to mild and moderate symptoms from MS and is to be
used in conjunction with physical therapy and indicated as a short
term treatment (14 weeks) chronic balance deficit due to
mild-to-moderate traumatic brain injury and is to be used in
conjunction with physical therapy. The PoNS is an investigational
medical device in the United States, the European Union, and
Australia, and is currently under review for clearance by the FDA
and AUS Therapeutic Goods Administration. PoNS Treatment is
currently not commercially available in the United States, the
European Union or Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.
Jack Powell
Vice President
investorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024